Davapyridine API

Name	Davapyridine
Chinese name	达伐吡啶
Cas Number	504-24-5
Source	Europe
Qualifications	USDMF/-/-/-/-

Davalpyridine was approved by the US FDA on January 22, 2010, and was approved by the European EMA on July 20, 2011. Dalvpyridine has been shown to increase the conduction of action potentials in demyelinated axons by inhibiting potassium ion channels and improve the walking status of patients with multiple sclerosis (MS). The results of clinical trials showed that the walking speed of MS patients treated with davalpyridine was faster than that of patients receiving placebo. In July 2019, a study published in "Neurology" pointed out that compared with other multiple sclerosis drugs, dalvapidine can also improve the information processing speed (IPS) impairment of multiple sclerosis. The average sales of davalpyridine in the three years from 2016 to 2018 were around US$600 million. Globally, multiple sclerosis affects the lives of approximately 2.3 million people. It is estimated that by 2022, the market for multiple sclerosis drugs will reach 23 billion U.S. dollars, and davapyridine will surely occupy an important position in this.

Hot Tags: davapyridine api, China, suppliers, manufacturers, factory, customized, price, pricelist, in stock, Idebenone API, Bosentan API, Canagliflozin API, Bivalrudine API, Pregabalin API, Escitalopram Oxalate API

• Previous: Cyclobenzaprine API
• Next: Shacubatril And Valsartan Sodium API